ALPK1 Agonists Modulate Immune Response for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective solutions for modulating inflammation and immune responses in treating inflammatory diseases, cancers, and infections, particularly in activating alpha protein kinase 1 (ALPK1) for therapeutic benefits.
Innovation Solution
The use of bacterial metabolites such as D-glycero-β-D-manno-heptose 1,7-bisphosphate (HBP) and its derivatives, including HMP-1bP and H1b-ADP, as ALPK1 agonists to activate downstream signaling pathways, enhance pro-inflammatory cytokine expression, and demonstrate synergistic anti-tumor effects when co-administered with immune checkpoint inhibitors and immune modulators.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used for modulating inflammation and immune responses, then existing therapeutic approaches are maintained, but effective treatment of inflammatory diseases, cancers, and infections is not achieved
Solution Approach 1:
The patent changes the molecular target parameter by identifying and activating ALPK1 kinase as a novel therapeutic target. By using small molecule compounds to activate ALPK1, the patent modifies the biochemical parameter of immune cell signaling, leading to enhanced cytokine production and improved anti-tumor immunity. This parameter change resolves the contradiction by providing a new mechanism that is both effective and adaptable for treating multiple diseases.
Solution Approach 2:
The patent introduces small molecule compounds as intermediary substances that mediate between the administered agent and the immune system. These compounds act as ALPK1 activators, serving as molecular mediators that trigger downstream signaling pathways including NF-κB, MAPK, and STAT activation. This intermediary approach enables effective immune modulation without directly manipulating complex immune cells, resolving the technical contradiction.
2Reliability
If ALPK1 activation is achieved through bacterial metabolites, then pro-inflammatory cytokine expression increases, but complexity of administering multiple compounds arises
Solution Approach 1:
The patent merges the functions of multiple bacterial metabolites (HBP, HMP-1bP, H1b-ADP) into a single small molecule compound structure that can activate ALPK1. By combining the essential structural features responsible for ALPK1 activation into one molecule, the patent simplifies the treatment regimen while maintaining reliable immune response activation. This merging principle resolves the contradiction between effective cytokine induction and treatment complexity.
Solution Approach 2:
The patent extracts the essential ALPK1-activating property from complex bacterial metabolites and isolates it into simplified small molecule compounds. By taking out only the critical molecular features needed for ALPK1 activation and removing unnecessary complexity from the original bacterial metabolite structures, the patent achieves reliable immune activation with simpler administration. This extraction approach resolves the technical contradiction.
3Adaptability or versatility
If novel ALPK1-activating compounds are developed, then new therapeutic approach is provided, but lack of effective methods for activating ALPK1 must be overcome
Solution Approach 1:
The patent performs preliminary identification and characterization of ALPK1 as a viable therapeutic target before developing activating compounds. Through preliminary studies demonstrating ALPK1's role in immune cell signaling and its potential for disease treatment, the patent establishes a reliable foundation for subsequent compound development. This preliminary action resolves the contradiction by ensuring the novel approach is based on a validated, reliable target.
Solution Approach 2:
The patent replaces the natural biological system (bacterial metabolites) with a synthetic chemical system (small molecule compounds). By substituting the complex biological production and administration of bacterial metabolites with synthetically produced small molecules, the patent creates a novel therapeutic approach that is more reliable and controllable. This mechanics substitution resolves the technical contradiction between novelty and reliability.
Data Source
AI summary
The disclosure provides compositions and methods related to activating alpha-kinase 1 (ALPK1) for modulating an immune response and treating or preventing cancer, infection, inflammation and related diseases and disorders as well as potentiating an immune response to a target antigen. The disclosure also provides heterocyclic compounds of formula (I) as agonists of alpha protein kinase 1 (ALPK1) and their use in activating ALPK1, modulating an immune response and treating diseases such as cancer, wherein A1, A2, L1, L2, L3, Z1, Z2, W1, W2, R1, R2, R3, R4, R5, R6 and R7 are defined herein.